Literature DB >> 12706007

Isoliquiritigenin inhibits the growth of prostate cancer.

Motohiro Kanazawa1, Yoshiko Satomi, Yoichi Mizutani, Osamu Ukimura, Akihiro Kawauchi, Toshiyuki Sakai, Masaki Baba, Toru Okuyama, Hoyoku Nishino, Tsuneharu Miki.   

Abstract

OBJECTIVE: Isoliquiritigenin, one of the components in the root of Glycyrrhiza glabra L., is a member of the flavonoids, which are known to have an anti-tumor activity in vitro and in vivo. In this study, we investigated the anti-tumor effect of isoliquiritigenin on prostate cancer in vitro.
METHODS: DU145 and LNCaP prostate cancer cell lines were used as targets. We examined the effects of isoliquiritigenin on cell proliferation, cell cycle regulation and cell cycle-regulating gene expression. Further, we investigated the effects of isoliquiritigenin on the GADD153 mRNA and protein expression, and promoter activity.
RESULTS: Isoliquiritigenin significantly inhibited the proliferation of prostate cancer cell lines in a dose-dependent and time-dependent manner. Fluorescence-activated cell sorting (FACS) analysis indicated that isoliquiritigenin induced S and G2/M phase arrest. Isoliquiritigenin enhanced the expression of GADD153 mRNA and protein associated with cell cycle arrest. Further, isoliquiritigenin stimulated transcriptional activity of GADD153 promoter dose-dependently.
CONCLUSION: These findings suggest that isoliquiritigenin is a candidate agent for the treatment of prostate cancer and GADD153 may play an important role in isoliquiritigenin-induced cell cycle arrest and cell growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706007     DOI: 10.1016/s0302-2838(03)00090-3

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  26 in total

1.  Isoliquiritigenin inhibits the growth of multiple myeloma via blocking IL-6 signaling.

Authors:  Xiangzheng Chen; Yangping Wu; Yangfu Jiang; Yan Zhou; Yuxi Wang; Yuqin Yao; Cheng Yi; Lantu Gou; Jinliang Yang
Journal:  J Mol Med (Berl)       Date:  2012-05-31       Impact factor: 4.599

2.  New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer.

Authors:  Juan Rodrigues; Claudia Abramjuk; Luis Vásquez; Neira Gamboa; José Domínguez; Bianca Nitzsche; Michael Höpfner; Radostina Georgieva; Hans Bäumler; Carsten Stephan; Klaus Jung; Michael Lein; Anja Rabien
Journal:  Pharm Res       Date:  2010-12-24       Impact factor: 4.200

Review 3.  The role of chalcones in suppression of NF-κB-mediated inflammation and cancer.

Authors:  Vivek R Yadav; Sahdeo Prasad; Bokyung Sung; Bharat B Aggarwal
Journal:  Int Immunopharmacol       Date:  2010-12-22       Impact factor: 4.932

4.  Protective Effects of Isoliquiritigenin on LPS-Induced Acute Lung Injury by Activating PPAR-γ.

Authors:  Wenbin Zhang; Gui Wang; Shujun Zhou
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

5.  Dietary chalcones with chemopreventive and chemotherapeutic potential.

Authors:  Barbora Orlikova; Deniz Tasdemir; Frantisek Golais; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2011-02-04       Impact factor: 5.523

6.  Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.

Authors:  R Mehrian-Shai; C D Chen; T Shi; S Horvath; S F Nelson; J K V Reichardt; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

7.  Effects of isoliquiritigenin on ovarian antral follicle growth and steroidogenesis.

Authors:  Sharada Mahalingam; Liying Gao; Jacqueline Eisner; William Helferich; Jodi A Flaws
Journal:  Reprod Toxicol       Date:  2016-10-20       Impact factor: 3.143

8.  Sensitivity and resistance towards isoliquiritigenin, doxorubicin and methotrexate in T cell acute lymphoblastic leukaemia cell lines by pharmacogenomics.

Authors:  Mahmoud Youns; Yu-Jie Fu; Yuan-Gang Zu; Anne Kramer; V Badireenath Konkimalla; Bernhard Radlwimmer; Holger Sültmann; Thomas Efferth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-07-29       Impact factor: 3.000

9.  Isoliquiritigenin in licorice functions as a hepatic protectant by induction of antioxidant genes through extracellular signal-regulated kinase-mediated NF-E2-related factor-2 signaling pathway.

Authors:  Sang Mi Park; Jong Rok Lee; Sae Kwang Ku; Il Je Cho; Sung Hui Byun; Sang Chan Kim; Sook Jahr Park; Young Woo Kim
Journal:  Eur J Nutr       Date:  2015-11-22       Impact factor: 5.614

10.  Isoliquiritigenin inhibits cell proliferation and migration through the PI3K/AKT signaling pathway in A549 lung cancer cells.

Authors:  Tao Tian; Jinpeng Sun; Jianxin Wang; Yanchun Liu; Haitao Liu
Journal:  Oncol Lett       Date:  2018-08-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.